Fully Human Antibodies, Acceleration of Discovery & Development
Mission
Individual Project Design, Fee for Service or Milestone-based
Contract Research, R&D Services
Partnered R&D, Collaborations, Licensing
Pipeline & Partnering
Follow a manual added link
Breaking News
Ymmunobio signs collaboration agreement with YUMAB
Swiss biotech company Ymmunobio AG will optimize its cancer-directed antibody development programme using YUMABs antibody discovery platform .
YUMAB® – Company
YUMAB is a world leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies. The YUMAB® platform is based on almost 30 years of continuous research by its founders in antibody discovery and engineering. It combines state of the art and next generation technologies from target to lead under one roof. YUMAB offers individually designed projects and business solutions for small biotech start-ups up to large biopharma companies.
News & Events
YUMAB celebrates 10th anniversary
January 10, 2023
What began as an academic start-up with the mission to facilitate biomedical translation is now a globally operating biotech company and a trusted service partner for therapeutic antibody development.
CRO / R&D Services
YUMAB offers contract research, technologies and R&D services for the discovery and development of fully human, therapeutic antibodies.
YUMAB® Platform, Partnering
YUMAB also provides partnering and collaboration strategies to provide access to our technologies and expertise for academic spin-offs and start-up companies without the burden of technology access fees.
Contact
SEND US AN E-MAIL
YUMAB GMBH
Phone: (+49) 531-481170-0
Email: info@yumab.com
YUMAB Inc.
1100 South Tower
225 Peachtree Street NE
Atlanta, GA 30303 – USA
Phone: (+49) 531 481170-0
Email: info@yumab.com
YUMAB GmbH
Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany
Phone: +49 531 481170-0
Fax: +49-531 481170-17
